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Abstract
Background: Clinical study reports (CSRs) are produced for marketing authorisation applications. They often
contain considerably more information about, and data from, clinical trials than corresponding journal publications. Use
of data from CSRs might help circumvent reporting bias, but many researchers appear to be unaware of their existence
or potential value. Our survey aimed to gain insight into the level of familiarity, understanding and use of CSRs, and to
raise awareness of their potential within the systematic review community. We also aimed to explore the potential
barriers faced when obtaining and using CSRs in systematic reviews.
Methods: Online survey of systematic reviewers who (i) had requested or used CSRs, (ii) had considered but not used
CSRs and (iii) had not considered using CSRs was conducted. Cochrane reviewers were contacted twice via
the Cochrane monthly digest. Non-Cochrane reviewers were reached via journal and other website postings.
Results: One hundred sixty respondents answered an open invitation and completed the questionnaire; 20/
160 (13%) had previously requested or used CSRs and other regulatory documents, 7/160 (4%) had considered but not
used CSRs and 133/160 (83%) had never considered this data source. Survey respondents mainly sought data from the
European Medicines Agency (EMA) and/or the Food and Drug Administration (FDA). Motivation for using CSRs
stemmed mainly from concerns about reporting bias 11/20 (55%), specifically outcome reporting bias 11/20
(55%) and publication bias 5/20 (25%). The barriers to using CSRs noted by all types of respondents included
current limited access to these documents (43 respondents), the time and resources needed to obtain and
include these data in evidence syntheses (n = 25) and lack of guidance about how to use these sources in
systematic reviews (n = 26).
Conclusions: Most respondents (irrespective of whether they had previously used them) agreed that access
to CSRs is important, and suggest that further guidance on how to use and include these data would help
to promote their use in future systematic reviews. Most respondents who received CSRs considered them to
be valuable in their systematic review and/or meta-analysis.
Background
The findings of clinical trials as reported in journal arti-
cles can sometimes be incomplete and misleading. There
is evidence that analyses and outcomes, including both
efficacy and harms, may be reported selectively such that
the true effects of treatments remain hidden [1–5]. Con-
sequently, those performing systematic reviews and
meta-analyses may need to take additional steps to lo-
cate, appraise and synthesise missing or inadequately re-
ported data in order to minimise the impact of such
reporting bias.
Clinical study reports (CSRs) are produced by pharma-
ceutical companies during a marketing authorisation ap-
plication for investigational medicinal products in the
EU, Japan and the USA. They are usually written in ac-
cordance with the ‘international conference on harmon-
isation of technical requirements for registration of
pharmaceuticals for human use’ (ICH) guideline on the
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structure and content of clinical study reports (ICH E3)
[6]. The purpose of the ICH guidance is to assist spon-
sors in developing a comprehensive trial report that is
complete, well-structured and easy for regulators to re-
view when making licencing decisions [7].
CSRs often include greater detail about trial design,
conduct and analysis; more complete results; and a more
reliable picture of strengths and weaknesses than journal
articles. Extracting data from CSRs and using these in
systematic reviews and meta-analyses may therefore pro-
vide more complete information and generate more reli-
able effect estimates [5, 8] than using data presented in
journal articles and help circumvent reporting bias [9,
10], particularly in relation to adverse events [11–13].
CSRs are becoming increasingly available and access-
ible following liberalisation of the European Medicines
Agency (EMA) policy related to public access to docu-
ments it holds relating to market access applications
[14]. Requests to the EMA for access to CSRs [15, 16]
have increased from 20 requests per month during the
first 2 years since 2010, to nearly 40 requests per
month post the initial 2-year period. The shift towards
improved transparency continued with the implementa-
tion of EMA’s Policy 0070 for publication of clinical
data of medicinal products for human use [17], and
other significant efforts to provide broader access to
clinical trial data. These include the Yale University
Open Data Access (YODA) Project [18], ClinicalStudy
DataRequest.com (CSDR) [19], the Duke Clinical
Research Institute (DCRI) [20], the AllTrials campaign
[21] and OpenTrials.net [22]. Some of the world’s lar-
gest pharmaceutical companies including Bristol-Myers
Squibb, GlaxoSmithKline, Johnson & Johnson, Lilly and
Roche have committed to data sharing [23]. CSRs are
now being promoted as a valuable resource in system-
atic reviews [5, 8, 9, 12], but because data sharing dir-
ectly via companies and other various platforms is still
relatively new, their existence may still be unknown to
many systematic review authors, and their utility is still
largely unexplored [24].
The US Agency for Healthcare Research and Quality
(AHRQ) has, amongst others, noted the value of search-
ing for ‘regulatory documents’ as a means of addressing
reporting bias [25]. The term ‘regulatory documents’ can
be used to describe a number of sources of information
other than CSRs, including Food and Drug Administra-
tion (FDA) approval documents on the Drugs@FDA web-
site (e.g. medical and statistical reviewer reports),
European Public Assessment Reports and any document
produced by, or held by, a regulatory agency.
The current version of the Cochrane Handbook, last
updated in 2011, encourages authors to search for un-
published data from pharmaceutical companies, trial
registers and trial result registries [26]. It does not,
however, discuss searching for or considering the use of
CSRs and other regulatory documents as sources of data,
which could partly explain why there have so far been
few Cochrane Reviews that have sought data from these
sources [11, 27]. This will be addressed in the major
revision currently in preparation—and is due for publi-
cation in late 2018.
Recognising the need to consider the potential value of
CSRs and other regulatory documents as a potential
source of data for Cochrane Reviews of pharmacological
interventions, Cochrane funded a project (of which this
survey was part) to explore the rationale for such use, and
the readiness of Cochrane reviewers to engage with regu-
latory material. To assess readiness and raise awareness,
we carried out a preliminary survey to gain insight to the
level of understanding, familiarity with and views on the
importance of CSRs and other regulatory documents. We
also explored what has previously motivated authors to
seek data from these sources, and barriers to using them
in Cochrane and other systematic reviews. We then car-
ried out a follow-up survey of respondents who had con-
sidered or used regulatory data in their systematic review,
to explore under what circumstances they thought it most
important to seek CSRs as a data source.
Methods
We conducted two online surveys involving authors
of Cochrane and other systematic reviews using the
data capture tool Qualtrics [28]. The initial survey
(Additional file 1) was open between 10 June and 19
September 2016. This was split into two releases, one
intended for Cochrane authors and the other for authors
of systematic reviews conducted outside of Cochrane. A
second (follow-up) survey (Additional file 2) was open
between 21 April and 31 May 2017.
The survey design included closed and open-ended
questions. Response options were discussed, drafted and
refined by the team. Question types included multiple
choice (check one/check all), free-text and comments.
‘Other (specify)’ responses were offered to capture more
detailed information that could not be collected using
structured multiple choice questions. Pilot testing of the
survey logic and flow was performed by AH and checked
by members of the research team and four independent
researchers. Revisions were made where necessary.
Ethics approval for the survey was granted by the
University of York Health Sciences Research Ethics and
Integrity Governance Committee.
Sample selection
The release of the initial survey intended for Cochrane
review authors was first announced in the Cochrane Di-
gest, which was emailed to all Cochrane authors on 10
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June 2016. It was then mentioned again in the Cochrane
Digest 2 weeks later. The release intended for authors of
non-Cochrane reviews was first advertised on the Uni-
versity of York Centre for Reviews and Dissemination
web site on the 25 June 2016 and then on the Systematic
Reviews journal web site. Links to this were also shared
via social media. The follow-up survey was sent only to
those Cochrane respondents who had previously consid-
ered or used regulatory data in their systematic review
and who had agreed during the first survey to participate
in the follow-up. Although several authors of this manu-
script have previously used data from regulatory docu-
ments, purposely none participated in either survey.
Domains of interest
The first survey questionnaires (Additional file 1) were
accessed via three separate links within the adverts cor-
responding to the respondent’s experience and under-
standing of the regulatory process aiming to capture
those who had:
1) ‘Requested’ (i.e. had used data from CSRs in their
review, or had received data but decided not to
include it, or were still awaiting for data)
2) ‘Considered’ using but not requested access to CSRs
3) ‘Never considered’ the use of regulatory
documentation such as CSRs
Respondents who had previously ‘requested’ CSRs or
other regulatory documents were asked to explain their
reasons for seeking and for using (or not using) the data,
the source and type of documents obtained and how the
data were used in the review. They were also asked to
describe any difficulties in using provided documents
and data, along with their views on the overall import-
ance of seeking data from these sources. Respondents
that had only ‘considered’ seeking regulatory documents
were asked about what sources they had considered uti-
lising and why they had decided against it; and whether
they thought this decision could have impacted on the
outcome of their review. Other domains of interest cap-
tured were the respondents’ views on the barriers to
using data from regulatory documents and what could
be done to promote and support the use of such data in
future systematic reviews. Those who had never
considered the use of regulatory documentation were
asked for their views on their potential value and
whether they might be encouraged to consider these
data in the future.
The follow-up survey (Additional file 2) explored what
factors might be considered most influential when decid-
ing whether to look beyond the information presented
in journal articles and to seek data from CSRs or other
regulatory documents for use in a systematic review. We
drew up an initial list of criteria on which respondents
were asked to comment (Table 1). Likert scales (very im-
portant, important, less important, not important and
unsure) were used to grade the importance of each cri-
terion. Respondents were also asked to identify any add-
itional criteria that would be important when deciding
whether to seek data from regulatory documents.
Data analysis
Descriptive statistics were used to express quantitative
responses including number(s), frequencies and percent-
ages. Verbatim responses were discussed within the team
and then tabulated. Responses were generally short and
wide-ranging and coded into categories by two research
team members (AH, KCD).
Since the two first survey questionnaires intended for
(a) Cochrane and (b) other systematic review authors
were the same, and because some respondents answered
the Cochrane questionnaire based on non-Cochrane re-
views and vice versa, and as there were few responses to
the non-Cochrane version, we combined and analysed
responses to both together (Fig. 1). We firstly checked
that there was no duplication or double counting of re-
views. We obtained publications for the systematic re-
views to which respondents referred (if provided by the
respondents in the survey). This enabled us to confirm
whether reviews were Cochrane reviews or not, and to
help resolve ambiguity in free-text responses (e.g. to
confirm which sources provided data and determine
how the data were used in a review). Authors were con-
tacted directly by email to confirm any other questions
we had about their review.
Results
A total of 160 respondents completed the first
(Cochrane and non-Cochrane) surveys (Fig. 1). Most re-
spondents (93%) were either a Cochrane review author
or an editor, 70% worked in academia, 40% were clini-
cians and 15% were involved in methods research. Of
the 160 respondents, 20 (13%) had previously requested
or used regulatory data in their review (13 in a Cochrane
review and 7 in a non-Cochrane review), 7 (4%) had
considered but not used regulatory data and 133 (83%)
had never considered using regulatory data.
In the follow-up survey, all 20 respondents who had
requested or used regulatory data in a systematic review
explained the rationale for making the request, 19 (95%)
provided information on where data were requested
from and 14 (70%) expressed an opinion about the type
of barriers involved. All 7 respondents who considered
using regulatory data but did not go on to seek it
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Table 1 Important criteria when considering data from clinical study reports and/or other regulatory data
Criteria Description of criteria
1 Monetary cost of the intervention on the healthcare budget (i.e. considering both the price of a course and the number of people in the
population that are being—or will be—treated)
2 Burden of disease of the indication this product is meant to treat/prevent
3 How many people are using or likely to use this product?
4 Product new to the market?
5 Product from a new drug class or has a new mechanism of action
6 Has important interactions with other drugs (e.g. drug-drug interactions)
7 High proportion of RCTs evaluating this product are industry funded
8 Prominent claims of safety and/or efficacy advantage of this product over currently available treatments
9 High degree of media attention surrounding this product
10 High proportion of trials of this product are unpublished
11 Post-marketing surveillance has identified safety concerns?
12 Important or standard outcome measures (also known as ‘endpoints’) have not been published
13 Concerns regarding a lack of published data on potential harms of the product
14 Marketing authorisation based on surrogate outcomes (rather than clinical outcomes)
15 When protocol(s) are publicly available
16 When statistical analysis plan(s) publicly available
17 Known errors or concerns about trial publications of this product
18 Important discrepancies between the journal publication and the trial registry entry?
Fig. 1 Flow diagram of combined survey responses with responses in each domain of interest
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explained the rationale for doing so, and 5 (71%) gave
the primary source of the data under consideration and
all responded about potential barriers. For the 133 re-
spondents that had never considered using regulatory
data, 91 (68%) indicated that they were familiar with the
regulatory process and types of documents produced, 39
(29%) were aware of where they might be able to access
regulatory documents such as CSRs and 61 (46%) be-
lieved that there are barriers to accessing and using data
from these sources.
Rationale for seeking data
For the 20 respondents who had requested or used regu-
latory data, 15 (75%) believed that regulatory data should
be used in systematic reviews and 5 (25%) said that they
should be used in some cases (Additional file 3: Table S1 ).
Seeking regulatory data was mainly driven by concerns
about reporting bias (specifically outcome reporting bias,
(n = 11), publication bias (n = 5) and potential for missing
data (n = 2) or underreporting of harms (n = 3). The same
concerns were raised by respondents who had considered
but not sought regulatory data, with 3/7 mentioning out-
come reporting bias, and 2/7 underreporting of harms.
For respondents who had never considered using regu-
latory data, 66/133 (50%) agreed that they should be
used in some cases, 43 (32%) said they should definitely
be used, 17 (13%) said they should not be used and 7
(5%) said they were unsure about using regulatory data
but did not provide any reasons. The reasons given by
the 17 respondents who said that regulatory data should
not be used were (n = 9) because the interventions ex-
plored in their reviews were non-pharmacological, (n =
5) because of lack of guidance on how to find and use
these data and (n = 3) because of the time required to
obtain the data.
Eight out of 133 (6%) respondents who had never
considered using regulatory documents indicated
that they had a detailed understanding and 83 (62%)
a basic understanding of the regulatory process
(Additional file 3: Table S2). However, 42/133 (32%)
respondents said that they had no understanding of
the regulatory process or the documentation in-
volved. The majority said that they were aware of
the ongoing debates and initiatives for improved ac-
cess to clinical trial data, specifically referring to the
AllTrials initiative [21], the Cochrane review of
neuraminidase inhibitors (which was based entirely
on regulatory data) [9] and other publications such
as Ben Goldacre’s Bad Science and Bad Pharma.
One respondent said that they had been involved in
crafting the EMA-led public deliberations regarding
the Policy 0070 in 2014, for access to clinical trial
data [17].
Source of evidence
Figure 2 shows where data access requests were made
(including the respondents who made multiple requests
to different sources). In total, there were 47 requests, of
which 19 (40%) were made to regulatory agencies of
which 10/19 (53%) were to the EMA with seven of the
requests successful in obtaining data; and 9/19 (47%)
were to the US Food and Drug Administration (FDA)
where five requests were successful. Eighteen out of 47
(38%) requests were made directly to pharmaceutical
companies; 8 to larger companies where six (75%) re-
quests were successful, and nine to smaller companies
where 3 (33%) requests were successful (Fig. 2). One
respondent noted a request made to the National Insti-
tute for Occupational Safety and Health in the USA
[29] for summary adverse events data, and another to
Health Canada. Only two requests were made to the
data sharing websites, Clinical Study Data Request
(CSDR) and YODA, where each was successful in
obtaining the data.
Amongst the 20 respondents who requested regula-
tory data (Table 2), 16 had obtained and used the data
in their review, two had not yet received the data and
their review was ongoing at the time of completing the
survey. One respondent said they had received only
baseline data and therefore did not include it in their
review, and one reported being unable to access the
full data because the study was stopped early due to
reports of unexpected side-effects. Clinical study re-
ports were acquired by 12 (60%) of the respondents.
Five obtained Medical and Statistical Reviews from
the FDA, two obtained European Public Assessment
Reports (EPARs), and one used other regulatory ma-
terial including a protocol, case report forms and ad-
verse reaction reports. Of the respondents who
obtained CSRs, nine (9/12 (75%)) had used data from
them to enable inclusion of unpublished trials in their
meta-analyses (n = 2) and to supplement published
data (n = 7). The other two respondents who obtained
CSRs used them in a narrative synthesis; one within a
NICE Single Technology Appraisal (STA).
Of the 133 respondents who had never considered
accessing regulatory data, 117 (88%) said they were
not aware (or were unsure) of where to access such
material (Additional file 3: Table S3). Sixteen (12%)
respondents said that they were aware of at least one
possible source of regulatory data. The EMA and
FDA were the two sources most commonly noted,
but other regulatory agencies mentioned were The
Health Products Regulatory Authority of Ireland,
Pharmaceuticals and Medical Devices Agency of Japan
and Therapeutic Good Administration Department of
Health Australia. Other sources mentioned but not
considered to be specific to regulatory data included
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the trial registries (ClinicalTrials.gov and the ISRCTN
register). The clinical study data request sharing platform
was considered by only one respondent. Pharmaceutical
companies and ethics committees were also mentioned as
other sources of data.
Barriers
Survey respondents were asked to express views on the
real or perceived barriers to accessing and using regula-
tory data including CSRs (Table 3). Over 70% of the au-
thors, who had used, requested or at least considered
regulatory data, reported there to be barriers compared
to 50% for respondents that had not considered the use
of such data. Specifically, for those who had requested
data, 14/20 (70%) identified barriers including ‘restricted
and limited sharing of trials data’, and the ‘time-con-
straints involved [in] searching and requesting the data’,
‘the lack of experience on extracting data and [lack of]
statistical guidance when including in a review’, ‘how and
where to search for individual trials’ and one mentioned
‘concerns over the quality of the data compared to the
journal publication’. For respondents who had only con-
sidered (but not requested) regulatory data, 6/7 (86%)
indicated similar barriers. For respondents who had not
considered using regulatory data, 67/133 (50%) believed
there to be barriers, whilst 56/133 (42%) were unsure.
The barriers noted by this group were also similar in cit-
ing ‘cost’, ‘time and resources required in searching and
requesting for data’ and also ‘limited access for the peer
reviewer’ which we understood to mean that data in-
cluded in regulatory documents were unpublished and
had therefore not been peer reviewed.
Criteria considered important for using regulatory data
Results of the follow-up, targeted survey designed to
identify the main reasons or triggers for authors seeking
and using data from regulatory documents, are shown in
Fig. 3. This was sent to the 21 first survey respondents
who had agreed to participate in a follow-up (6 respon-
dents to the first survey were unwilling to participate in
a follow-up). Fourteen of the 21 (66%) provided a re-
sponse. The following criteria were considered of most
importance (i.e. ‘very important’ or ‘important’) by all re-
spondents in deciding when it is most important to use
regulatory data in a systematic review: ‘discrepancies be-
tween publication and registry entry’, ‘known errors or
concerns about publications’, ‘concerns for a lack of pub-
lished data on harms of product’, ‘important outcome
measures (‘endpoints’) unpublished’, ‘safety concerns
identified in post-marketing surveillance’, ‘high propor-
tion of trials unpublished and/or industry funded’.
Between 9 (64%) and 13 (93%) respondents considered
‘marketing authorisation based on surrogate outcomes’,
‘safety or efficacy advantage over current treatments’,
‘product new to the market or from a new drug class’,
‘important drug-drug interactions’ and ‘monetary cost of
the intervention’ to be important.
Fig. 2 Sources of data for the respondents who requested regulatory/non-regulatory data and the success rate obtaining the data. *Larger companies
include GSK (n = 1 request (1: successful request)), Pfizer (n = 2 (2)), Eli Lilly (n = 1 (1)), Bristol-Myers Squibb (n = 2 (1)), Merck (n = 1 (0)),
Genentech (n = 1 (1)). **Smaller companies include (2) Helsinn, (2) Schering-Plough, (1) Salix Pharmaceuticals, (1) PharmaSwiss, (1) Cubist
Pharmaceuticals, (1) Pharmaxis, (1) Santhera. **(1) Request was made to the US’s National Institute for Occupational Safety and Health
(NIOSH) and the other to Health Canada
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Table 2 Description of data obtained and how they were used in the systematic reviews
Survey reply Source of data request(s) Data
obtained




Description of how data were used
1 Author, manufacturer Yes CSRs Yes ‘Summary statistics provided or
extracted from the extra
documentation were incorporated
into meta-analysis’
2 Unknown Yes CSRs Yes ‘Quantitative data about side effects
were included’
3 EMA, FDA Yes CSRs No ‘Data were not used in meta-analyses,
but rather in a narrative form instead’
4 EMA, FDA Yes EPARs and Medical Reviews No ‘Data was used to describe the
number of studies and the number
of studied drugs in results of search
criteria’
5 EMA, FDA, Multiple drug
companies
Yes FDA and EMA reports, Poster Yes ‘To add data on studies not aware of,
and to add outcomes to a published
study that were not itemised in the
journal publication’
6 Clinical investigator, EMA,
sponsor
Noβ No data were obtained N/A ‘Not provided by pharmaceutical
sponsor, possibly because study
stopped early due to unexpected
side effects, and raw data may never
have been compiled.’
7 FDA, Health Canada, NIOSH Yes Adverse event reports No ‘The data did not provide some of the
detail we would have liked, such as
indication for the drug, dosing etc.
We summarized the results in narrative
form but did not include in the
quantitative analyses of the data we
retrieved from published studies’
8 Clinical investigator, medical
director of company
Yes CSRs Yes ‘Assessed quality of the studies and
extracted data for use in forest plots
and description’
9 Clinical Study Data Request,
EMA, FDA
Other* Case report forms N/A ‘N/A as data not received’
10 Clinical investigator, EMA,
Pharmaceutical company
Other¥ Details of trial participants at
start of trial (baseline data and
info about randomisation)
No ‘Only data at start of trial was available’
11 EMA, GSK and FDA Yes Clinical and Statistical reviews
at FDA, CSRs
Yes ‘We checked the data for consistency
(across multiple published and
unpublished sources) and reported
in the systematic review the most
accurate and conservative estimates.
If needed, we contacted authors for
confirmation’
12 Pharmaceutical company Yes CSRs, IPD Yes ‘Data from CSRs & IPD were used in
evidence synthesis’
‘We know patient level data exists
but we were not given access to it
despite trying’
13 Pfizer Other* CSRs N/A€ ‘Extraction of data from Pfizer Medical
Information Report’
14 EMA, FDA Yes CSRs, protocol with appendices Yes ‘We extracted, compared and used
the aggregated effect estimates data
for predefined outcomes’
15 Helsinn, Merck and Pfizer Yes CSRs Yes ‘Where possible incorporated it as
more likely to be the correct data than
what was published’
16 EMA, FDA Yes FDA medical and statistical
reviews
Yes ‘Performed data extraction from these
sources. Compared with data from
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The two criteria deemed less important (by 6
(43%) to 9 (64%) of authors) included the public
availability of ‘statistical analysis plans’ and of
‘protocols’.
Respondents expressed divided opinion about whether
‘number of people using the product’, ‘high degree of
media attention surrounding the drug’ and ‘burden of
disease’ were important ‘triggers’.
Respondents suggested as other ‘triggers’ for seeking
and using of regulatory data: ‘the lack of clarity on pub-
lished trials’ and ‘when a small number of trials are avail-
able’. It was also noted that ‘regulatory data were
irrelevant for non-pharmacological intervention reviews
(e.g. surgical techniques, psychological interventions and
psychical therapy) and were therefore unable to use CSRs.’
Discussion
Summary of findings
In this survey, only 27/160 (17%) systematic review au-
thors had used, requested or considered using regulatory
data in their review and 133/160 (83%) had never
considered using such data. Respondents who had re-
quested regulatory documents had mainly sought
these from the EMA and the FDA. Other requests
were made to individual pharmaceutical companies,
Table 3 Barriers when seeking regulatory data for use in a Cochrane review
Requested/used regulatory data Considered regulatory data Not considered regulatory data
Survey question Total no. of responses: n (% of total responses)
Are there any barriers to using regulatory data? n = 20 n = 7 n = 133
Yes 14 (70) 6 (86) 67 (50)
No 2 (10) 0 (0) 10 (8)
Unsure 4 (20) 1 (14) 56 (42)
What were these barriers? n = 14 n = 5 n = 60
Restricted and limited sharing of data 8 4 31
Time-constraints 6 2 17
Lack of experience (inc. statistical) 4 1 21
Identifying/searching for trials 2 1 13
Quality of data 1 0 12
Cost 0 1 1
Effort/resources required 0 0 5
Limited access for peer reviewers* 0 0 1
*This referred to peer reviewers not having access to regulatory data during the peer review stage
Table 2 Description of data obtained and how they were used in the systematic reviews (Continued)
Survey reply Source of data request(s) Data
obtained




Description of how data were used
published sources’
17 EMA, NIOSH Yes N/A No ‘Excluded studies’
18 FDA Yes CSRs, FDA reports and IPD Yes ‘Data was used in place of publication’





Yes CSRs No ‘In narrative synthesis. However, some
of the data/text needed to be
removed before the final technology
assessment report is published under
the confidentiality agreement’.
N/A not applicable, FDA Food and Drug Administration, EMA European Medicine Agency, NIOSH The National Institute for Occupational Safety and Health
βResponse: ‘data not provided by pharmaceutical sponsor possibly because study was stopped early due to unexpected side effects and therefore the raw data
may not have been complied’
*Still awaiting data/updating review
¥Intended data requested was not available
€Intend to incorporate data in a meta-analysis
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but only one was made to a data sharing platform.
Respondents also described seeking data from the
clinical investigators or authors of published trials in
their responses, although these are clearly not usual
sources of regulatory documents, which may indicate
unfamiliarity with and a misunderstanding of the
question posed as being about any ‘unpublished data’
rather than specifically being focused on regulatory
documents.
Clinical study reports were acquired by 12/20 (60%)
of the respondents requesting data, but other regulatory
documents including Medical and Statistical Reviews
from the FDA (5/20 (25%)), European Public Assessment
Reports (EPARs) (2/20 (10%)), and protocols, case re-
port forms and post-marketing adverse reaction re-
ports were also obtained. For the respondents who
obtained CSRs, 9/12 (75%) had used the data in their
review, in order to include unpublished trials in their
meta-analyses and to supplement published data. Two
of the respondents were still waiting for the data, one
respondent noted that the pharmaceutical company
could not provide the data because the study for
which the request was made was stopped early due to
reports of unexpected side-effects and another re-
spondent reported that only baseline data were
provided.
At least two thirds of the respondents who requested
or considered utilising regulatory data reported a num-
ber of barriers to inclusion of such data in Cochrane re-
views including restrictions on accessing trial data, the
excessive time involved when waiting for data to be re-
leased and the resources, costs and effort required when
incorporating the data in a review.
The criteria considered to be most important in
triggering decisions to seek regulatory data include
situations where there are discrepancies between a
study publication and its corresponding trial registry
entry, known errors or concerns about publications
including a lack of data on harms and where import-
ant outcome measures (‘endpoints’) are not reported.
Fig. 3 Criteria considered most important when considering using regulatory data (n = 14)
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Safety concerns identified in post-marketing surveil-
lance, situations where a high proportion of trials
are unpublished and/or industry funded, and cases
where marketing authorization was based on sur-
rogate outcomes were also considered important in-
dicators of when it would be valuable to seek
regulatory data. The lack of availability of the trial
protocol and statistical analysis plan and media at-
tention about the drug were considered to be ‘less
important’. The cost of the intervention, disease bur-
den, population size and characteristics of the inter-
vention (new to market, interactions with other
drugs) were of more mixed opinion of importance
amongst authors.
Comparison with other research
A previous study [11] exploring the experiences of
Cochrane review authors when searching for, gaining
access to and using unpublished data found that a
large proportion of Cochrane review authors had
searched for unpublished data. Over half (913/1656
(55.1%)) of those who searched for unpublished data
were successful in finding it, and over 81% (651/794)
who sought these data went on to use them in their
review. In that study, most of the unpublished data
were obtained from ‘trialists or investigators’. Of 794
author requests in their study, 403/794 (51%) sought
summary data (e.g. mean, standard deviation, sample
size), 226/794 (29%) missing outcomes (e.g. quality of
life), 163/794 (21%) individual participant data (IPD),
96/794 (12%) results of alternative analysis (e.g.
intention to treat), 67/794 (8%) data on harms and
45/794 (6%) CSRs. Data from manufacturers were less
frequently used in these reviews. One of the concerns
outlined by the authors was that searching for un-
published data was time consuming, which aligns
with the opinions expressed by respondents in our
survey. Despite the perceived importance of CSRs in
providing information about adverse effects, a recent
study found that of 348 systematic reviews on ad-
verse effects published in 2014, not one of the re-
views had stated that they searched for or included
CSRs [27].
Another study [30] provided in-depth descriptions of
some of the experiences of researchers carrying out sys-
tematic reviews when searching for and gaining access
to unpublished data. That work aimed to provide gui-
dance on best practices for identifying, obtaining and
using unpublished data from a variety of sources, but
did not consider regulatory documents. The results
suggested that authors differed in their understanding
of what was meant by unpublished data, including
specific outcomes and methodological details. They
also reported that data requests were often seen as
time consuming and that including such data was con-
sidered to be labour-intensive. There was agreement,
however, by the majority of authors that searching for
and considering unpublished data in systematic re-
views was important for helping to improve the ge-
neral public health.
Accessing regulatory data
Based on interactions with the community, it seems
that many researchers undertaking systematic reviews
are still unaware of the various data sharing platforms
that provide access to regulatory trial documents and
datasets. This may be partly because such data shar-
ing platforms are relatively new and evolving. Further-
more, the limited formal guidance available to
systematic review authors explaining how to identify
and access regulatory data might also explain why
they are rarely used or considered. For example, as
noted above, the current version of the Cochrane
Handbook does not currently discuss regulatory docu-
ments and the data that these might contain, where
to find these data, or how to include them [31]. In
our study, participants were asked what could be
done to promote and support greater use of CSRs
and other regulatory documents. Most agreed that
there is a need for greater understanding about these
documents and for guidance on how to search for
and access such data. Some mentioned the need for
statistical guidance on how to include the data in evi-
dence synthesis, even though the type of (aggregate)
data that these documents contain are largely no dif-
ferent to the type of data presented in journal articles
and do not need to be handled and analysed differ-
ently (data from patient narratives or case report
forms included within a CSR will need different hand-
ling). There were also concerns about how to inter-
pret highly statistical content within the documents,
e.g. efficacy and safety listings data which may require
statistical/software expertise to help extract and or-
ganise the data.
Limitations of study
As most of the survey questions captured free-text
response(s), the replies were varied and some were
unclear or lacked enough detail to understand fully.
However, responses were discussed by two team
members (AH and KCD) who agreed upon an appro-
priate classification of response.
Although this survey concerned regulatory documents,
and in particular CSRs, it was apparent even from the
relatively low numbers who responded that some may
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have misunderstood some of the questions posed. The
term ‘regulatory data’ was not defined in the survey, as
we were interested in learning how respondents inter-
preted this and this may explain why some authors who
had used other types of data (e.g. IPD or other summary
data obtained from trial authors) responded in the sur-
vey. In a number of the responses, authors had made
multiple data requests for regulatory data and other
data, but it was not always clear in their responses which
data or document sources were actually used in their
systematic review or meta-analysis. The review refer-
ences provided, or obtained by contacting the authors,
helped to resolve some of these uncertainties about how
the data were used in reviews.
The initial survey of Cochrane authors was adver-
tised twice in the Cochrane methods digest, which is
circulated by email to the whole Cochrane commu-
nity. We do not know how many people actually re-
ceived and opened the email, and consequently how
many people read the invitation to opt into the sur-
vey. This might explain the low response rate (2.2%
calculated using the known figure of 7273 registered
Cochrane reviews over the last 2 years as the denom-
inator) compared with that achieved in the survey by
Schroll et al. [11] (37%) which sent invitations to par-
ticipate directly to review authors. The Schroll survey
may also have achieved higher numbers of responses
because most Cochrane authors understand the con-
cept of using ‘unpublished data’ whereas fewer may
have been familiar with the idea of using regulatory
documentation. Furthermore, the use of unpublished
data is relevant to all systematic reviews, whilst regu-
latory documents apply only to reviews of interven-
tions that have made, or intended to make, an
application for market authorisation. As respondents
in our survey may have been more likely to have a
greater understanding of the regulatory process and
documents produced, than authors who did not par-
ticipate in our survey, our sample might not be repre-
sentative of all authors of systematic reviews. The
survey cannot be used, and indeed was not intended,
to draw any conclusions about the proportion of re-
viewers accessing CSRs. Rather it aimed to gain
insight into the level of familiarity with regulatory
sources of data, particularly amongst Cochrane au-
thors, and to get some indication of the potential
level of ‘buy in’ to future encouragement to use these
sources in Cochrane Reviews, and what support may
be needed to facilitate this.
Conclusions
The results from this survey show that data from CSRs
and other regulatory documents are being used in a
small number of Cochrane Reviews. The survey
revealed that the vast majority of respondents thought
that accessing and using CSRs and other regulatory
documents in systematic reviews was important, sug-
gesting that the Cochrane community may be ready
and willing to engage with this source of evidence.
The time taken and resource needed to request, re-
ceive and use the data was cited as a major barrier, as
was the lack of formal guidance on access to and use
of documents produced for regulatory purposes. There
is a pressing need to develop materials to help review
authors identify questions and topics where using
regulatory data is likely to matter most and which
should therefore adopt and invest in such an approach,
and to help them navigate regulatory documents and
incorporate data from them in Cochrane and other
systematic reviews.
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